2023
DOI: 10.1159/000533266
|View full text |Cite
|
Sign up to set email alerts
|

Cardiac Troponin T and NT-proBNP for Prediction of 30-Day Readmission or Death in Patients with Acute Dyspnea: Data from the Akershus Cardiac Examination 2 Study

Rahul Bhatnagar,
Kristian Berge,
Ragnhild Røysland
et al.

Abstract: Introduction: N-terminal pro-B-type natriuretic peptide (NT-proBNP) and cardiac troponin T (cTnT) measurements are recommended in patients with acute dyspnea. We aimed to assess the prognostic merit of cTnT compared to NT-proBNP for 30-day readmission or death in patients hospitalized with acute dyspnea. Methods: We measured cTnT and NT-proBNP within 24 hours in 314 patients hospitalized with acute dyspnea and adjudicated the cause of the index admission. Time to first event of readmission or death ≤30 days a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 37 publications
0
1
0
Order By: Relevance
“…In this issue of Cardiology, Bhatnagar et al [14] studied and compared the properties of cTnT and NT-proBNP for predicting short-term prognosis (all-cause in-hospital or 30-day mortality and 30-day readmissions) in unselected patients coming to emergency department with acute dyspnea. They aimed to determine the better prognostic biomarker for patients with acute dyspnea to improve risk assessment, reduce readmission rates, and ultimately reduce the cost associated with readmissions.…”
mentioning
confidence: 99%
“…In this issue of Cardiology, Bhatnagar et al [14] studied and compared the properties of cTnT and NT-proBNP for predicting short-term prognosis (all-cause in-hospital or 30-day mortality and 30-day readmissions) in unselected patients coming to emergency department with acute dyspnea. They aimed to determine the better prognostic biomarker for patients with acute dyspnea to improve risk assessment, reduce readmission rates, and ultimately reduce the cost associated with readmissions.…”
mentioning
confidence: 99%